GA
SUPN icon

Geneva Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Geneva Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-21,540
Closed -$674K – 788
2017
Q1 		$674K Buy
21,540
+11,726
+119% +$314K 0.01% 432
2016
Q4 		$248K Buy
+9,814
New +$219K ﹤0.01% 630

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Geneva Advisors's SUPN Position: Q2 2017 in Review

Geneva Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 21,540 shares — an estimated $674K sold.

Geneva Advisors first reported a position in SUPN in Q4 2016 and held it in 2 quarters. The position peaked at $674K in Q1 2017. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

  • Geneva Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Geneva Advisors sold 21,540 Supernus Pharmaceuticals shares in Q2 2017, an estimated $674K.
  • Geneva Advisors first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Geneva Advisors's Supernus Pharmaceuticals position peaked at $674K in Q1 2017.
  • 265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.